Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VX 814 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

    • Most Recent Events

    • 21 Nov 2020 This trial has been completed in Ireland , according to European Clinical Trials Database record.
    • 14 Oct 2020 Status changed from recruiting to discontinued, according to a Vertex Pharmaceuticals media release.
    • 14 Oct 2020 According to a Vertex Pharmaceuticals media release, based on the safety and pharmacokinetic (PK) profile of VX-814 observed to date in this study, the company has decided to stop dosing in the trial and will discontinue development of VX-814.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top